Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 3 study of alirocumab in pediatric homozygous familial hypercholesterolemia
NL-OMON48896Phase 3Active, not recruiting
- Sponsor
- Sanofi Clinical Study Unit
- Start
- Sep 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of alirocumab in homozygous familial hypercholesterolemia (HoFH), sponsored by Sanofi Clinical Study Unit. Primary endpoint: Primary efficacy endpoint. Started Sep 2018; status: active, not recruiting.
02
Drugs
alirocumab
03
Conditions
homozygous familial hypercholesterolemia (HoFH)
Beyond the preview
Go deeper on NL-OMON48896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48896.